|1.||Ratain, M J: 2 articles (02/2002 - 02/2001)|
|2.||Vokes, E E: 2 articles (02/2002 - 02/2001)|
|3.||Finizio, M: 2 articles (02/2001 - 04/2000)|
|4.||Sekar, Kanagaraj: 1 article (01/2014)|
|5.||Biswas, Ansuman: 1 article (01/2014)|
|6.||Prasad, Karothu Durga: 1 article (01/2014)|
|7.||Balaji, Kithiganahalli N: 1 article (01/2014)|
|8.||Guru Row, Tayur N: 1 article (01/2014)|
|9.||Trinath, Jamma: 1 article (01/2014)|
|10.||Utz, Rebecca L: 1 article (10/2011)|
|1.||Breast Neoplasms (Breast Cancer)
06/01/1991 - "CI-941 has shown significant activity in patients with advanced breast cancer and these agents appear to have a bright future."
06/01/1999 - "Losoxantrone, an anthrapyrazole in clinical development, has shown promising single-agent activity in metastatic breast cancer. "
08/01/1994 - "Other agents that have undergone Phase II testing in breast cancer include vinorelbine, edatrexate, and losoxantrone. "
05/01/1993 - "Two anthrapyrazoles, DuP 937 and DuP 941, novel anticancer drugs with phase 2 activity against breast cancer, were as effective as doxorubicin in the oncomice. "
01/01/1992 - "Taxol, navelbine, and anthrapyrazole CI-941 have been found to have major efficacy against breast cancer, with response rates exceeding 50%. "
05/01/1995 - "A 42-year-old woman with metastatic breast carcinoma treated with only DuP-941 developed, and died of, heart failure for which no other explanation was apparent. "
01/01/2001 - "BBR 3438 exhibited a unique profile of preclinical activity with a superior efficacy against prostatic carcinoma models compared to reference compounds (doxorubicin and losoxantrone). "
01/01/2001 - "The novel 9-aza-anthrapyrazole BBR 3438 was significantly more effective than doxorubicin and losoxantrone (DuP-941) in two of the three tested prostate carcinoma models. "
02/01/2001 - "To obtain information on the routes of elimination of the drug, a study was conducted in four patients with advanced solid tumors, which involved intravenous administration of 100 microCi of [14C]losoxantrone for a total dose of 50 mg/m(2) during the first course of losoxantrone therapy. "
04/01/2002 - "In contrast to these results, human tumor HepG2 cells did not show any CI-941 biotransformation after incubation."
02/01/2001 - "Collectively, these data indicate that fecal excretion of unmetabolized drug via biliary and/or intestinal excretion is the primary pathway of intravenously administered losoxantrone elimination in cancer patients with refractory solid tumors."
02/01/2001 - "Elimination pathways of [14C]losoxantrone in four cancer patients."
01/01/1998 - "This work sought to assess the sensitivity and selectivity of UV spectral matching for monitoring the impurity profile of drugs, using as an illustration DuP 941, an anti-cancer drug under development. "
|5.||Prostatic Neoplasms (Prostate Cancer)
04/01/2000 - "Patients with metastatic prostate cancer progressing on androgen ablation therapy without demonstrable antiandrogen withdrawal response were treated with losoxantrone 50 mg/m2 i.v. bolus every 21 days. "
04/01/2000 - "A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer."
04/01/2000 - "Our purpose in this study was to determine the efficacy and toxicity of losoxantrone (DuP-941), an anthrapyrazole, in patients with metastatic hormone-refractory prostate cancer. "